TB Vaccines Show Safety but Limited Protection in Large Trial

Key Highlights

• Two candidate Tuberculosis vaccines, VPM1002 and Immuvac, demonstrated strong safety profiles
• No overall protection against pulmonary TB or latent infection
• VPM1002 showed ~50% protection against extrapulmonary TB
• Notably effective in children (6–14 years) for certain TB outcomes
• Limited efficacy in underweight populations, highlighting nutritional gaps

Can New TB Vaccines Fill the BCG Gap?

Despite decades of reliance on the BCG vaccine, tuberculosis remains a persistent global health burden. A large-scale trial published in The BMJ evaluated two investigational vaccines, VPM1002 and Immuvac, across over 12,700 participants in India.

The study targeted household contacts of confirmed TB patients, a group at high risk of infection. Participants aged 6 years and above were randomized to receive either vaccine or placebo and followed for 38 months.

While both vaccines were safe and generated immune responses, they did not prevent overall TB incidence or latent TB infection, which remains a key challenge in TB control strategies.

Where Do These TB Vaccines Show Clinical Value?

The most clinically relevant finding lies in disease progression prevention. Both vaccines demonstrated the ability to reduce the transition from latent TB infection to active disease.

Notably:

• VPM1002 showed 50.4% efficacy against extrapulmonary TB (EPTB) across all age groups
• In adults aged 36–60 years, efficacy rose to 79.5% for EPTB
• In pediatric populations (6–14 years), VPM1002 showed protection against all TB forms
• Immuvac showed selective protection against EPTB in younger children

These findings are significant because extrapulmonary TB, affecting organs beyond the lungs, often carries higher morbidity and mortality risks than pulmonary TB.

However, neither vaccine demonstrated effectiveness in underweight individuals, reinforcing the need for integrated nutrition and immunization strategies in TB-endemic regions.

What This Means for TB Prevention Strategies

For healthcare professionals, this trial underscores a nuanced but important shift in TB vaccine development. While these candidates may not replace the BCG vaccine, they could serve as adjunct tools in preventing disease progression, especially in high-risk populations.

The study also reflects real-world clinical diversity, including individuals with comorbidities such as diabetes. However, limitations such as pandemic-related disruptions and geographic specificity suggest that further global trials are needed.

Explore All Infectious Disease CME Conferences & Online Courses

Key Takeaways for Clinical Practice

• Do new TB vaccines prevent infection? → No, but they may reduce disease progression
• Which vaccine showed the best results? → VPM1002 for extrapulmonary TB
• Are they safe? → Yes, both vaccines demonstrated safety and immunogenicity
• What gaps remain? → Limited efficacy in undernourished populations and latent TB prevention

Source:

BMJ Group